Advertisement

Topics

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

08:54 EDT 20 Oct 2017 | SCRIP

Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights...

      

Related Stories

 

Original Article: Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

NEXT ARTICLE

More From BioPortfolio on "Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...